SCHEDULE 13G/A: Frazier Life Sciences Funds and Affiliates Disclose Significant Passive Stake in Palvella Therapeutics
Beneficial Ownership Amendment
Frazier Life Sciences Public Fund and its affiliated entities, along with key individuals, have filed an amended Schedule 13G/A disclosing their passive beneficial ownership in Palvella Therapeutics, Inc., with certain individuals holding over 6% of the common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 525,732 shares of Palvella Therapeutics, Inc. Common Stock, representing 4.8% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 155,023 shares, representing 1.4% of the class.
- Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 3,914 shares, representing 0.0% of the class.
- Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 5,343 shares, representing 0.0% of the class.
- James N. Topper and Patrick J. Heron each beneficially own 690,012 shares, representing 6.3% of the class, through their shared voting and investment power over the combined holdings of the Frazier Life Sciences funds.
- Albert Cha and James Brush each beneficially own 680,755 shares, representing 6.2% of the class, through their shared voting and investment power over the holdings of Frazier Life Sciences Public Fund and Public Overage Fund.
- Daniel Estes beneficially owns 5,343 shares, representing 0.0% of the class, through his shared voting and investment power over the holdings of Frazier Life Sciences XI, L.P.
- The percentages are calculated based on 11,018,747 shares of Common Stock outstanding as of March 25, 2025, as reported in Palvella Therapeutics, Inc.'s Annual Report on Form 10-K filed on March 31, 2025.
- The filing is an amendment to a Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a routine regulatory disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors and their affiliates, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 2016-03-29 | Date of Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron. |
| 2017-07-31 | Date of Power of Attorney filed with the SEC for James N. Topper and Patrick J. Heron (referenced in signatures). |
| 2021-08-16 | Date of Power of Attorney filed with the SEC for Albert Cha and James Brush. |
| 2022-04-18 | Date of Power of Attorney filed with the SEC for Daniel Estes. |
| 2025-03-25 | Date on which 11,018,747 shares of Common Stock were outstanding, as per the Issuer's 10-K. |
| 2025-03-31 | Date of Event Which Requires Filing of this Statement; also the filing date of the Issuer's Annual Report on Form 10-K. |
| 2025-05-15 | Date of filing of this Schedule 13G/A and Joint Filing Agreement. |
Keywords
Palvella Therapeutics, Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, SEC Filing, Common Stock, Investment Funds, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.